1 of 3
FEATURED COMPANIES
- AmpliPhi Biosciences Corp
- CRS Bio
- Knopp Biosciences LLC
- Lyra Therapeutics
- Nota Laboratories LLC
- Paratek Pharmaceuticals
- MORE
The global demand for Sinusitis treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Sinusitis pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Sinusitis pipeline companies from advancing their products into Phase 3 or Phase 4.
Sinusitis Report Description
The H1- 2019 pipeline review report on Sinusitis pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Sinusitis pipeline compounds.
The Sinusitis pipeline guide presents information on all active drugs currently being developed for Sinusitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Sinusitis pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Sinusitis drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Sinusitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Sinusitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Sinusitis pipeline report includes
Sinusitis Report Description
The H1- 2019 pipeline review report on Sinusitis pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Sinusitis pipeline compounds.
The Sinusitis pipeline guide presents information on all active drugs currently being developed for Sinusitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Sinusitis pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Sinusitis drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Sinusitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Sinusitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Sinusitis pipeline report includes
- An overview of Sinusitis disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Sinusitis pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Sinusitis pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Sinusitis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- AmpliPhi Biosciences Corp
- CRS Bio
- Knopp Biosciences LLC
- Lyra Therapeutics
- Nota Laboratories LLC
- Paratek Pharmaceuticals
- MORE
1.1 List of Tables
1.2 List of Figures
2. Global Sinusitis Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. Executive Summary
3.1 Sinusitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Sinusitis pipeline, H1- 2019
3.5 Mechanism of Action wise Sinusitis Pipeline Candidates
4. AmpliPhi Biosciences Corp Sinusitis Pipeline Details
4.1 AmpliPhi Biosciences Corp Business Profile
4.2 AmpliPhi Biosciences Corp Sinusitis Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. AnaptysBio Inc Sinusitis Pipeline Details
5.1 AnaptysBio Inc Business Profile
5.2 AnaptysBio Inc Sinusitis Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. CRS Bio Sinusitis Pipeline Details
6.1 CRS Bio Business Profile
6.2 CRS Bio Sinusitis Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. GlycoMira Therapeutics Inc Sinusitis Pipeline Details
7.1 GlycoMira Therapeutics Inc Business Profile
7.2 GlycoMira Therapeutics Inc Sinusitis Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. Intrexon Corp Sinusitis Pipeline Details
8.1 Intrexon Corp Business Profile
8.2 Intrexon Corp Sinusitis Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. Knopp Biosciences LLC Sinusitis Pipeline Details
9.1 Knopp Biosciences LLC Business Profile
9.2 Knopp Biosciences LLC Sinusitis Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. Kyorin Pharmaceutical Co Ltd Sinusitis Pipeline Details
10.1 Kyorin Pharmaceutical Co Ltd Business Profile
10.2 Kyorin Pharmaceutical Co Ltd Sinusitis Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. Kyowa Hakko Kirin Co Ltd Sinusitis Pipeline Details
11.1 Kyowa Hakko Kirin Co Ltd Business Profile
11.2 Kyowa Hakko Kirin Co Ltd Sinusitis Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. Lyra Therapeutics Sinusitis Pipeline Details
12.1 Lyra Therapeutics Business Profile
12.2 Lyra Therapeutics Sinusitis Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. Merck & Co Inc Sinusitis Pipeline Details
13.1 Merck & Co Inc Business Profile
13.2 Merck & Co Inc Sinusitis Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. Nota Laboratories LLC Sinusitis Pipeline Details
14.1 Nota Laboratories LLC Business Profile
14.2 Nota Laboratories LLC Sinusitis Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. OptiNose US Inc Sinusitis Pipeline Details
15.1 OptiNose US Inc Business Profile
15.2 OptiNose US Inc Sinusitis Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. Paratek Pharmaceuticals Sinusitis Pipeline Details
16.1 Paratek Pharmaceuticals Business Profile
16.2 Paratek Pharmaceuticals Sinusitis Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. Pfizer Inc Sinusitis Pipeline Details
17.1 Pfizer Inc Business Profile
17.2 Pfizer Inc Sinusitis Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. ProclaRx LLC Sinusitis Pipeline Details
18.1 ProclaRx LLC Business Profile
18.2 ProclaRx LLC Sinusitis Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19. Roche Sinusitis Pipeline Details
19.1 Roche Business Profile
19.2 Roche Sinusitis Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20. Therabron Therapeutics Inc Sinusitis Pipeline Details
20.1 Therabron Therapeutics Inc Business Profile
20.2 Therabron Therapeutics Inc Sinusitis Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
20. Latest Sinusitis Drug Pipeline Developments, 2019
21. Appendix
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
1.2 List of Figures
2. Global Sinusitis Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. Executive Summary
3.1 Sinusitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Sinusitis pipeline, H1- 2019
3.5 Mechanism of Action wise Sinusitis Pipeline Candidates
4. AmpliPhi Biosciences Corp Sinusitis Pipeline Details
4.1 AmpliPhi Biosciences Corp Business Profile
4.2 AmpliPhi Biosciences Corp Sinusitis Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. AnaptysBio Inc Sinusitis Pipeline Details
5.1 AnaptysBio Inc Business Profile
5.2 AnaptysBio Inc Sinusitis Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. CRS Bio Sinusitis Pipeline Details
6.1 CRS Bio Business Profile
6.2 CRS Bio Sinusitis Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. GlycoMira Therapeutics Inc Sinusitis Pipeline Details
7.1 GlycoMira Therapeutics Inc Business Profile
7.2 GlycoMira Therapeutics Inc Sinusitis Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. Intrexon Corp Sinusitis Pipeline Details
8.1 Intrexon Corp Business Profile
8.2 Intrexon Corp Sinusitis Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. Knopp Biosciences LLC Sinusitis Pipeline Details
9.1 Knopp Biosciences LLC Business Profile
9.2 Knopp Biosciences LLC Sinusitis Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. Kyorin Pharmaceutical Co Ltd Sinusitis Pipeline Details
10.1 Kyorin Pharmaceutical Co Ltd Business Profile
10.2 Kyorin Pharmaceutical Co Ltd Sinusitis Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. Kyowa Hakko Kirin Co Ltd Sinusitis Pipeline Details
11.1 Kyowa Hakko Kirin Co Ltd Business Profile
11.2 Kyowa Hakko Kirin Co Ltd Sinusitis Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. Lyra Therapeutics Sinusitis Pipeline Details
12.1 Lyra Therapeutics Business Profile
12.2 Lyra Therapeutics Sinusitis Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. Merck & Co Inc Sinusitis Pipeline Details
13.1 Merck & Co Inc Business Profile
13.2 Merck & Co Inc Sinusitis Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. Nota Laboratories LLC Sinusitis Pipeline Details
14.1 Nota Laboratories LLC Business Profile
14.2 Nota Laboratories LLC Sinusitis Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. OptiNose US Inc Sinusitis Pipeline Details
15.1 OptiNose US Inc Business Profile
15.2 OptiNose US Inc Sinusitis Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. Paratek Pharmaceuticals Sinusitis Pipeline Details
16.1 Paratek Pharmaceuticals Business Profile
16.2 Paratek Pharmaceuticals Sinusitis Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. Pfizer Inc Sinusitis Pipeline Details
17.1 Pfizer Inc Business Profile
17.2 Pfizer Inc Sinusitis Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. ProclaRx LLC Sinusitis Pipeline Details
18.1 ProclaRx LLC Business Profile
18.2 ProclaRx LLC Sinusitis Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19. Roche Sinusitis Pipeline Details
19.1 Roche Business Profile
19.2 Roche Sinusitis Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20. Therabron Therapeutics Inc Sinusitis Pipeline Details
20.1 Therabron Therapeutics Inc Business Profile
20.2 Therabron Therapeutics Inc Sinusitis Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
20. Latest Sinusitis Drug Pipeline Developments, 2019
21. Appendix
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3
- AmpliPhi Biosciences Corp
- AnaptysBio Inc
- CRS Bio
- GlycoMira Therapeutics Inc
- Intrexon Corp
- Knopp Biosciences LLC
- Kyorin Pharmaceutical Co Ltd
- Kyowa Hakko Kirin Co Ltd
- Lyra Therapeutics
- Merck & Co Inc
- Nota Laboratories LLC
- OptiNose US Inc
- Paratek Pharmaceuticals
- Pfizer Inc
- ProclaRx LLC
- Roche
- Therabron Therapeutics Inc
Note: Product cover images may vary from those shown
